

Author Index

BR: Book review

CR: Conference report

A

- Agranat, I. and Caner, H., Intellectual property and chirality of drugs 313
- Ahlberg, C., Visual exploration of HTS databases: bridging the gap between chemistry and biology 370
- Ahnfelt-Rønne, I., *see* Ankersen, M. 497
- Allen, C.M., *see* Sharman, W.M. 507
- Amess, B., *see* Page, M. 55
- Ankersen, M., Hansen, T.K., Ahnfelt-Rønne, I. and Kappelgaard, A.M., Growth hormone secretagogues – recent advances and applications 497
- Appleton, T., Combinatorial chemistry and HTS – feeding a voracious process (CR) 398

B

- Bauer, J., Hüll, M., Fiebich, B.L., Schumann, G. and Lieb, K., Anti-inflammatory substances – a new therapeutic option in Alzheimer's disease 275
- Beeley, N.R.A., *Peptidomimetic Protocols in the series Methods in Molecular Medicine* (BR) 454
- Bennet, T., *see* Mere, L. 363
- Bhagwat, S.S., Manning, A.M., Hoekstra, M.F. and Lewis, A., Gene-regulating protein kinases as important anti-inflammatory targets 472
- Binns, R. and Driscoll, B., Europe says 'hello Dolly' to the biotech directive 27
- Blunck, M., *see* Spaltmann, F. 17
- Bohic, S., Damiens, C. and Padrines, M., Potential use of infrared microspectroscopy to study drug-related structural changes in bone 443
- Bolger, R., High-throughput screening: new frontiers for the 21st century 251 (CR), 410 (corrigendum)
- Bottomley, S., Bioinformatics 42, 240, 482
- Bradley, D., Paralysis prevention drug 53
- Bradley, D., Action shot of crystalline HIV 107
- Bradley, D., Peptide simulation – it's all in the folds 153

- Bradley, D., Overcoming HIV resistance 201
- Bradley, D., Single enzyme may hold key to cancer treatment 250
- Bradley, D., Enzyme links build better antibiotics 345
- Bradley, D., Plastics in cancer therapy 540
- Brooks, G. and La Thangue, N.B., The cell cycle and drug discovery: the promise and the hope 455
- Broske, L., *see* Cox, K. 232

C

- Caner, H., *see* Agranat, I. 313
- Chaby, R., Strategies for the control of LPS-mediated pathophysiological disorders 209
- Chandraratna, R., *see* DiSepio, D. 222
- Coassin, P., *see* Mere, L. 363
- Coffen, D.L., *see* Powers, D.G. 377
- Cohen, D., *see* Dyer, M. 109
- Corey, D., *see* Pitts, A. 155
- Coruzzi, G., Histamine H₃ receptors and the gastrointestinal tract 571
- Cox, K., Dunn-Meynell, K., Korfmacher, W., Broske, L. and Nomeir, A., Novel *in vivo* procedure for rapid pharmacokinetic screening of discovery compounds in rats 232

D

- Damiens, C., *see* Bohic, S. 443
- DiSepio, D., Chandraratna, R. and Nagpal, S., Novel approaches for the treatment of psoriasis 222
- Driscoll, B., *see* Binns, R. 27
- Dunn-Meynell, K., *see* Cox, K. 232
- Dyer, M., Cohen, D. and Herrling, P., Functional genomics: from genes to new therapies 109

E

- Ecker, D.J. and Griffey, R.H., RNA as a small molecule drug target: doubling the value of genomics 420
- Elsevier Trends, Trends Online editorial 197

- England, P.J., *see* Mere, L. 363
- England, P.J., Discovering ion channel modulators – making the electrophysiologist's life more interesting 391

F

- Farina, C. and Gagliardi, S., Selective inhibitors of the osteoclast vacuolar proton ATPase inhibitors as novel bone antiresorptive agents 163
- Fenwick, S., Will the mirror crack? 3
- Fiebich, B.L., *see* Bauer, J. 275

G

- Gagliardi, S., *see* Farina, C. 163
- Ganesan, A., Targeting protein-protein interactions: the HIV protease 387
- Ganz, T., *see* Rivas, L. 254
- González, J., Oades, K., Leychkis, Y., Harootunian, A. and Negulescu, P., Cell-based assays and instrumentation for screening ion-channel targets 431
- Gorse, D., *see* Lahana, R. 257
- Green, I. and Chabrier, P-E., Nitric oxide: from basic research to clinical applications (CR) 47, 196 (erratum)
- Griffey, R.H., *see* Ecker, D.J. 420
- Groettrup, M. and Schmidtke, G., Selective proteasome inhibitors: modulation of antigen presentation? 63
- Gurwitz, D., Molecular cancer target: PI-3-kinase 96
- Gurwitz, D., Novel 5-HT_{1A}-receptor agonists: F11440, MKC242 and BAYx3702 142
- Gurwitz, D., Pharmacogenetic-oriented drug design 151

H

- Hansen, T.K., *see* Ankersen, M. 497
- Harootunian, A., *see* González, J. 431
- Hart, T., Combinatorial approaches to chemistry and biology (CR) 538
- Haupts, U.M., *see* Pope, A.J. 350
- Hawkins, D.R., Use and value of metabolism databases 466

- Heinemann, J.A., How antibiotics cause antibiotic resistance 72
- Herrling, P., *see* Dyer, M. 109
- Hewick, R., *see* Wang, J. 129
- Hird, N.W., Automated synthesis: new tools for the organic chemist 265
- Hoekstra, M.F., *see* Bhagwat, S.S. 472
- Hoepping, A., *see* Smith, M.P. 322
- Horvat, J., Sugar-based peptidomimetics 386
- Hughes, D., Dizzying but scary: looking towards R&D in 2005 (CR) 393
- Hughes, D., Sorting woods from trees 198
- Hughes, J., Genomic technologies in drug discovery and development 6
- Hüll, M., *see* Bauer, J. 275
- J**
- Jain, K.K., Strategies and technologies in functional genomics (CR) 50
- Jain, K.K., Molecular labels, signalling and detection (CR) 346
- Johnson, D., The discovery–development interface has become the new interfacial phenomenon 535
- Johnson, K.M., *see* Smith, M.P. 322
- K**
- Kaczorek, M., *see* Lahana, R. 257
- Kain, S.R., Green fluorescent protein (GFP): applications in cell-based assays for drug discovery 304
- Kaiser, S.M. and Quinn, R.J., Adenosine receptors as potential therapeutic targets 542
- Kappelgaard, A.M., *see* Ankersen, M. 497
- Korfmacher, W., *see* Cox, K. 232
- Kozikowski, A.P., *see* Smith, M.P. 322, 429 (correction)
- Kozlowski, R.Z., Industrial–academic collaboration: a bridge too far? 487
- Kristek, F., Nitric oxide disbalance and structural alteration of the cardiovascular system 243
- L**
- La Thangue, N.B., *see* Brooks, G. 455
- Lahana, R. and Roux, F., *Combinatorial Chemistry and Molecular Diversity in Drug Discovery* (BR) 203
- Lahana, R., Rees, A., Kaczorek, M. and Gorse, D., Molecular diversity and its analysis 257
- Lahana, R., How many leads from HTS? 447
- Lauer, S., *see* Nolan, J. 173
- Lawrence, R.N., Rediscovering natural product biodiversity (CR) 449
- Lawrence, R.N., Enhancing information sharing 494
- Lecanu, L. and Plotkine, M., Profile 292
- Leon, D., Innovation and the workplace 181
- Levin, J., *see* Noble, D. 10
- Lewis, A., *see* Bhagwat, S.S. 472
- Leychkis, Y., *see* González, J. 431
- Lieb, K., *see* Bauer, J. 275
- Lloyd, A., Natural antitumour agent, N-type calcium channel blockers, Leukotriene D₄-receptor antagonists, Phosphodiesterase inhibitors 39
- Lloyd, A., Substituted pyrazoles as novel D₄-receptor ligands, Novel fluoroquinolone antibiotics, MEK inhibitors, LHRH-receptor antagonist, p38 kinase inhibitor 93
- Lloyd, A., Cholesterol and plasma lipid modifying agents, Endothelin ET_B-receptor antagonists, Dual D₂-receptor and β_2 -adrenoceptor agonists, 4,5-Diarylimidazoles as selective cyclooxygenase inhibitors, Osteoclast V-ATPase inhibitor 139
- Lloyd, A., $\alpha_4\beta_1$ Integrin inhibitors, Novel antibacterial agents 186
- Lloyd, A., 5-HT₆-receptor antagonist, Novel nonsteroidal androgen-receptor agonist, Novel antithrombotic therapy 238
- Lloyd, A., Novel structural classes of p38 kinase inhibitors, Modulation of multidrug resistance by taxinine derivatives, Controlling gastric emptying, Tetrahydrobenzindoles as selective 5-HT₇-receptor antagonists, Dual inhibitors of phosphodiesterase type 4 and matrix metalloproteinases, Emerging therapeutic targets 289
- Lloyd, A., 3-(Piperazinylpropyl)indoles: h5-HT_{1D} receptor agonists, Novel non-xanthine adenosine A₁-receptor antagonist, Novel inhibitors of carboxypeptidase G₂: applications in ADEPT therapy, High-affinity GABA_A-receptor ligands, Selective cyclooxygenase-2 inhibitors, (3-Substituted benzyl)thiazolidine-2,4-diones: new antihyperglycaemic agents, Novel anti-osteoporosis agent, N-type calcium channel blockers 333
- Lloyd, A., Antitumour activity of thioester derivatives of leinamycin, Thrombin inhibitors, Novel MMP inhibitors, IL-6 secretion inhibitor, Nonsteroidal androgen receptor agonists, Sugar-based peptidomimetics 384
- Lloyd, A., ET_A-receptor antagonists, Dual acting α_1 -adrenoceptor antagonist and steroid 5 α -reductase inhibitor, Mast cell trypase inhibitors, DNA-ligase IV, Cathepsin K – a target for the treatment of osteoporosis 440
- Lloyd, A., Hexose-related imidazolidinones, Antimycobacterial agents, Leukocyte elastase and macrophage metalloelastase inhibitors, High-affinity retinoic acid receptor-antagonists 480
- Lloyd, A., Orally active arginine vasopressin-receptor antagonists, Influenza sialidase inhibitor, Neuropeptide YY₁-receptor antagonists 530
- Lloyd, A., Histamine H₃-receptor antagonists, Antimalarial drugs, NR1/2B NMDA-receptor antagonists, D₃-receptor antagonists, Apoptotic protease activating factor-1 568
- Logan, C., Expediting the preclinical development process (CR) 452
- M**
- Manning, A.M., *see* Bhagwat, S.S. 472
- Marks, M.J., *see* Wonnacott, S. 490
- Mere, L., Bennet, T., Coassin, P., England, P. and Rink, T., Miniaturized FRET assays and microfluidics: Key components for ultra-high-throughput screening 363
- Merritt, A., *Combinatorial Chemistry* (BR) 54
- Moore, K., *see* Pope, A.J. 350

Moore, K.J., Utilization of mouse models in the discovery of human disease genes 123

Mousa, S.A., Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond 552

N

Nagpal, S., *see* DiSepio, D. 222

Nair, M., *Antifolate Drugs In Cancer Therapy* (BR) 492

Negulescu, P., *see* González, J. 431

Newman, W., Chemokines and their receptors (CR) 299

Noble, D., Levin, J. and Scott, W., Biological simulations in drug discovery 10

Nolan, J., Lauer, S., Prossnitz, E.R. and Sklar, L.A., Flow cytometry: a versatile tool for all phases of drug discovery 173

Nomeir, A., *see* Cox, K. 232

O

Oades, K., *see* González, J. 431

Ovadia, M., Metalloproteinase inhibitors in snakebite envenomations 532

P

Padrines, M., *see* Bohic, S. 443

Page, M., Amess, B., Rohlf, C., Stubberfield, C. and Parekh, R., Proteomics: a major new technology for the drug discovery process 55

Parekh, R., *see* Page, M. 55

Persidis, A., Corporate intelligence in biotechnology 204

Persidis, A., Biotechnology clusters 297

Persidis, A., Biotechnology perspectives in Europe (CR) 301

Pitts, A. and Corey, D., The telomerase challenge: an unusual problem in drug discovery 155

Plotkine, M., *see* Lecanu, L. 292

Pope, A.J., Haupts, U.M. and Moore, K., Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice 350

Powers, D.G. and Coffen, D.L., Convergent automated parallel synthesis 377

Prossnitz, E.R., *see* Nolan, J. 173

Q

Quinn, R.J., *see* Kaiser, S.M. 542

R

Ramm, P., Imaging systems in assay screening 401

Rees, A., *see* Lahana, R. 257

Rink, T., A Boston T party (CR) 249

Rink, T., *see* Mere, L. 363

Rivas, L. and Ganz, T., Eukaryotic antibiotic peptides: not only a membrane business (CR) 254

Rohlf, C., *see* Page, M. 55

Rose, D., Microdispensing technologies in drug discovery 411

Roux, F., *see* Lahana, R. 203

S

Sansom, C., Pharmacokinetic and toxicology screening (CR) 199

Sansom, C., A new opening for large-protein therapeutics 537

Saunders, J. and Tarby, C.M., Opportunities for novel therapeutic agents acting at chemokine receptors 80

Schmidtke, G., *see* Groettrup, M. 63

Schumann, G., *see* Bauer, J. 275

Scott, W., *see* Noble, D. 10

Sharman, W.M., Allen, C.M. and van Lier, J.E., Photodynamic therapeutics: basic principles and clinical applications 507

Shaw, I., Drug Discovery Technologies '99 conference (CR) 343

Shinkai, H., Recent developments in oral hypoglycaemic agents 283

Simon, S., Role of organelle pH in tumor cell biology and drug resistance 32

Sklar, L.A., *see* Nolan, J. 173

Smith, M.P., Hoepfing, A., Johnson, K.M., Trzcinska, M. and Kozikowski, A.P., Dopaminergic agents for the treatment of cocaine abuse 322

Spaltmann, F., Blunck, M. and Ziegelbauer, K., Computer-aided target selection – prioritizing targets for antifungal drug discovery 17

Spence, P., Genomics: the race is on 103

Stubberfield, C., *see* Page, M. 55

Stylli, H., Reaping the rewards 341

Sverdrup, F., *see* Taylor, M. 562

Szymkowski, D.E., *Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors* (BR) 9

T

Tally, F.P., Researchers reveal ways to defeat 'superbugs' (CR) 395

Tarby, C.M., *see* Saunders, J. 80

Taylor, M., Wiederholt, K. and Sverdrup, F., Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination 562

Terrett, N., Combinatorial chemistry 41, 95, 141, 187, 239, 294, 336, 386, 442, 481, 532, 570

Thomas, S., Genomics and intellectual property rights 134

Tranter, D., Preparing for the new millennium 1

Trzcinska, M., *see* Smith, M.P. 322

V

van Lier, J.E., *see* Sharman, W.M. 507

W

Walker, M.A., Hepatitis C virus: an overview of current approaches and progress 518

Wallace, R.W., Does antisense make sense? 4

Wallace, R.W., Pharmacogenomics: the next logical step 105

Wang, J. and Hewick, R., Proteomics in drug discovery 129

Warhurst, D.C., Corrigendum 147

Warmus, J., Integrating combinatorial chemistry into the discovery pipeline (CR) 7

Wiederholt, K., *see* Taylor, M. 562

Williamson, A., The Merck Gene Index project 115

Wójcik, C., Inhibition of the proteasome as a therapeutic approach 188

Wolmark, Y., Alzheimer's disease – the therapeutic era (CR) 149

Wonnacott, S. and Marks, M.J., Nicotine: not just for cigarettes anymore (CR) 490

Wright, C.W., *Medicinal Plants of the World* (BR) 154

Z

Zidek, Z., Immunomodulatory antivirals 97

Ziegelbauer, K., *see* Spaltmann, F. 17